Abstract Background Amebiasis, a notifiable infectious disease in Japan, had shown an increasing trend in reported cases until 2017 when the insurance-covered serum antibody testing reagent was discontinued.
← all excerpts
P-1292. Impact of Discontinuation of Serum Antibody Test Reagents on the Diagnosis of Amebiasis in Japan (2013-2022)
1
—
—